STOCK TITAN

[8-K] CervoMed Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Concorde International Group Ltd (CIGL) filed a Form 6-K announcing an auditor change effective 1 Aug 2025. The Audit Committee dismissed Kreit & Chiu CPA LLP, whose 2023-24 audit opinions were unqualified and contained no scope or GAAP reservations. The firm reported no disagreements with management over accounting matters during the past two fiscal years.

The Committee simultaneously appointed Assentsure PAC to audit FY 2025 and review the 1H-2025 results. The Company confirms Assentsure was not previously consulted on any accounting or reporting issues.

While there were no reportable events tied to Kreit & Chiu, the filing reiterates previously disclosed material weaknesses in internal control over financial reporting—chiefly segregation-of-duties gaps, insufficient IFRS training, and ineffective review controls. Kreit & Chiu’s letter to the SEC agreeing with these disclosures is filed as Exhibit 15.1.

The change signals a governance shift but keeps the audit timeline intact; investors should monitor remediation of the cited control weaknesses ahead of the FY 2025 audit.

Concorde International Group Ltd (CIGL) ha presentato un modulo 6-K annunciando un cambio di revisore a partire dal 1° agosto 2025. Il Comitato di Revisione ha revocato l'incarico a Kreit & Chiu CPA LLP, le cui opinioni di revisione per il 2023-24 erano senza rilievi e non contenevano riserve di portata o di principi contabili. Lo studio non ha segnalato disaccordi con la direzione su questioni contabili negli ultimi due esercizi fiscali.

Contestualmente, il Comitato ha nominato Assentsure PAC per la revisione del bilancio 2025 e la revisione dei risultati del primo semestre 2025. La Società conferma che Assentsure non è stata precedentemente consultata su questioni contabili o di rendicontazione.

Anche se non sono emersi eventi segnalabili legati a Kreit & Chiu, il documento ribadisce le criticità materiali già comunicate nel controllo interno sulla rendicontazione finanziaria, in particolare lacune nella segregazione dei compiti, formazione IFRS insufficiente e controlli di revisione inefficaci. La lettera di Kreit & Chiu alla SEC che concorda con queste comunicazioni è allegata come Exhibit 15.1.

Il cambiamento indica un mutamento nella governance ma mantiene invariato il calendario della revisione; gli investitori dovrebbero monitorare la risoluzione delle debolezze di controllo segnalate prima della revisione del 2025.

Concorde International Group Ltd (CIGL) presentó un formulario 6-K anunciando un cambio de auditor efectivo a partir del 1 de agosto de 2025. El Comité de Auditoría despidió a Kreit & Chiu CPA LLP, cuyas opiniones de auditoría para 2023-24 fueron sin salvedades y no contenían reservas de alcance ni de principios contables. La firma reportó ningún desacuerdo con la gerencia sobre asuntos contables durante los últimos dos años fiscales.

Simultáneamente, el Comité nombró a Assentsure PAC para auditar el año fiscal 2025 y revisar los resultados del primer semestre de 2025. La Compañía confirma que Assentsure no fue consultada previamente sobre cuestiones contables o de reporte.

Aunque no hubo eventos reportables relacionados con Kreit & Chiu, la presentación reitera las debilidades materiales previamente divulgadas en el control interno sobre la información financiera, principalmente brechas en la segregación de funciones, capacitación insuficiente en IFRS y controles de revisión ineficaces. La carta de Kreit & Chiu a la SEC que está de acuerdo con estas divulgaciones se presenta como Exhibit 15.1.

El cambio señala un giro en la gobernanza pero mantiene el calendario de auditoría intacto; los inversionistas deben monitorear la remediación de las debilidades de control citadas antes de la auditoría del año fiscal 2025.

Concorde International Group Ltd (CIGL)는 2025년 8월 1일부터 감사인 변경을 발표하는 Form 6-K를 제출했습니다. 감사위원회는 2023-24 회계연도에 무조건 의견을 제시하고 범위 제한이나 회계기준(GAAP) 유보사항이 없었던 Kreit & Chiu CPA LLP를 해임했습니다. 해당 법인은 지난 2개 회계연도 동안 경영진과 회계 문제에 대해 이견이 없었다고 보고했습니다.

위원회는 동시에 2025 회계연도 감사 및 2025년 상반기 실적 검토를 위해 Assentsure PAC를 임명했습니다. 회사는 Assentsure가 과거에 회계 또는 보고 문제에 대해 자문을 받은 적이 없었다고 확인했습니다.

Kreit & Chiu와 관련된 보고 가능한 사건은 없었지만, 이번 제출 서류는 내부회계관리제도의 중대한 약점—주로 직무 분리 미흡, IFRS 교육 부족, 비효율적인 검토 통제—을 이전에 공개한 내용을 재확인합니다. Kreit & Chiu가 SEC에 제출한 이와 관련된 동의 서한은 Exhibit 15.1로 첨부되어 있습니다.

이번 변경은 거버넌스 변화를 의미하지만 감사 일정은 유지됩니다. 투자자들은 2025 회계연도 감사 전에 언급된 통제 약점 개선을 주시해야 합니다.

Concorde International Group Ltd (CIGL) a déposé un formulaire 6-K annonçant un changement d’auditeur effectif au 1er août 2025. Le comité d’audit a révoqué Kreit & Chiu CPA LLP, dont les opinions d’audit pour 2023-24 étaient sans réserve et ne comportaient aucune restriction de portée ni réserve relative aux normes comptables. Le cabinet n’a signalé aucun désaccord avec la direction sur des questions comptables au cours des deux derniers exercices fiscaux.

Le comité a simultanément nommé Assentsure PAC pour auditer l’exercice 2025 et examiner les résultats du premier semestre 2025. La société confirme qu’Assentsure n’a pas été consultée auparavant sur des questions comptables ou de reporting.

Bien qu’aucun événement signalable lié à Kreit & Chiu n’ait été identifié, le dépôt rappelle les faiblesses importantes précédemment divulguées dans le contrôle interne sur la communication financière – principalement des lacunes dans la séparation des fonctions, une formation IFRS insuffisante et des contrôles de révision inefficaces. La lettre de Kreit & Chiu adressée à la SEC, approuvant ces divulgations, est jointe en annexe 15.1.

Ce changement marque une évolution de la gouvernance tout en maintenant le calendrier d’audit ; les investisseurs doivent suivre la correction des faiblesses de contrôle citées avant l’audit de l’exercice 2025.

Concorde International Group Ltd (CIGL) hat ein Formular 6-K eingereicht, in dem ein Wechsel des Abschlussprüfers zum 1. August 2025 angekündigt wird. Der Prüfungsausschuss hat Kreit & Chiu CPA LLP abberufen, dessen Prüfungsurteile für 2023-24 uneingeschränkt waren und keine Einschränkungen im Umfang oder bei den GAAP enthielten. Die Firma meldete in den letzten zwei Geschäftsjahren keine Meinungsverschiedenheiten mit dem Management zu Rechnungslegungsfragen.

Gleichzeitig wurde Assentsure PAC mit der Prüfung des Geschäftsjahres 2025 sowie der Überprüfung der Ergebnisse des ersten Halbjahres 2025 beauftragt. Das Unternehmen bestätigt, dass Assentsure vorher nicht zu Buchhaltungs- oder Berichtsthemen konsultiert wurde.

Obwohl keine meldepflichtigen Ereignisse im Zusammenhang mit Kreit & Chiu vorlagen, wiederholt die Einreichung zuvor offengelegte wesentliche Schwächen in der internen Kontrolle über die Finanzberichterstattung – hauptsächlich Lücken bei der Aufgabentrennung, unzureichende IFRS-Schulungen und ineffektive Überprüfungskontrollen. Das Schreiben von Kreit & Chiu an die SEC, das diesen Angaben zustimmt, ist als Exhibit 15.1 beigefügt.

Der Wechsel signalisiert eine Veränderung in der Governance, hält jedoch den Prüfungszeitplan ein; Investoren sollten die Behebung der genannten Kontrollschwächen vor der Prüfung für das Geschäftsjahr 2025 beobachten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Auditor switch is routine; control weaknesses linger—net neutral to slightly negative risk profile.

Kreit & Chiu’s clean opinions limit historical risk, and the absence of disputes reduces red-flag concerns. However, management still faces three material control deficiencies that could affect FY 2025 reporting quality. The move to Assentsure may improve oversight, yet any audit re-scoping could lengthen timelines or raise fees. Until remediation plans are disclosed, the filing is moderately negative for risk-adjusted valuation.

TL;DR: Governance optics mixed—orderly transition, but unresolved ICFR weaknesses hurt credibility.

The Board followed best practice—Audit Committee initiated change, secured successor before year-end cycles, and disclosed SEC-required items, including an agreeing letter from the former auditor. Still, repeating material weaknesses for a third year points to structural oversight issues. Successful remediation and a clean 2025 opinion would be credit-positive; failure could trigger listing or regulatory scrutiny.

Concorde International Group Ltd (CIGL) ha presentato un modulo 6-K annunciando un cambio di revisore a partire dal 1° agosto 2025. Il Comitato di Revisione ha revocato l'incarico a Kreit & Chiu CPA LLP, le cui opinioni di revisione per il 2023-24 erano senza rilievi e non contenevano riserve di portata o di principi contabili. Lo studio non ha segnalato disaccordi con la direzione su questioni contabili negli ultimi due esercizi fiscali.

Contestualmente, il Comitato ha nominato Assentsure PAC per la revisione del bilancio 2025 e la revisione dei risultati del primo semestre 2025. La Società conferma che Assentsure non è stata precedentemente consultata su questioni contabili o di rendicontazione.

Anche se non sono emersi eventi segnalabili legati a Kreit & Chiu, il documento ribadisce le criticità materiali già comunicate nel controllo interno sulla rendicontazione finanziaria, in particolare lacune nella segregazione dei compiti, formazione IFRS insufficiente e controlli di revisione inefficaci. La lettera di Kreit & Chiu alla SEC che concorda con queste comunicazioni è allegata come Exhibit 15.1.

Il cambiamento indica un mutamento nella governance ma mantiene invariato il calendario della revisione; gli investitori dovrebbero monitorare la risoluzione delle debolezze di controllo segnalate prima della revisione del 2025.

Concorde International Group Ltd (CIGL) presentó un formulario 6-K anunciando un cambio de auditor efectivo a partir del 1 de agosto de 2025. El Comité de Auditoría despidió a Kreit & Chiu CPA LLP, cuyas opiniones de auditoría para 2023-24 fueron sin salvedades y no contenían reservas de alcance ni de principios contables. La firma reportó ningún desacuerdo con la gerencia sobre asuntos contables durante los últimos dos años fiscales.

Simultáneamente, el Comité nombró a Assentsure PAC para auditar el año fiscal 2025 y revisar los resultados del primer semestre de 2025. La Compañía confirma que Assentsure no fue consultada previamente sobre cuestiones contables o de reporte.

Aunque no hubo eventos reportables relacionados con Kreit & Chiu, la presentación reitera las debilidades materiales previamente divulgadas en el control interno sobre la información financiera, principalmente brechas en la segregación de funciones, capacitación insuficiente en IFRS y controles de revisión ineficaces. La carta de Kreit & Chiu a la SEC que está de acuerdo con estas divulgaciones se presenta como Exhibit 15.1.

El cambio señala un giro en la gobernanza pero mantiene el calendario de auditoría intacto; los inversionistas deben monitorear la remediación de las debilidades de control citadas antes de la auditoría del año fiscal 2025.

Concorde International Group Ltd (CIGL)는 2025년 8월 1일부터 감사인 변경을 발표하는 Form 6-K를 제출했습니다. 감사위원회는 2023-24 회계연도에 무조건 의견을 제시하고 범위 제한이나 회계기준(GAAP) 유보사항이 없었던 Kreit & Chiu CPA LLP를 해임했습니다. 해당 법인은 지난 2개 회계연도 동안 경영진과 회계 문제에 대해 이견이 없었다고 보고했습니다.

위원회는 동시에 2025 회계연도 감사 및 2025년 상반기 실적 검토를 위해 Assentsure PAC를 임명했습니다. 회사는 Assentsure가 과거에 회계 또는 보고 문제에 대해 자문을 받은 적이 없었다고 확인했습니다.

Kreit & Chiu와 관련된 보고 가능한 사건은 없었지만, 이번 제출 서류는 내부회계관리제도의 중대한 약점—주로 직무 분리 미흡, IFRS 교육 부족, 비효율적인 검토 통제—을 이전에 공개한 내용을 재확인합니다. Kreit & Chiu가 SEC에 제출한 이와 관련된 동의 서한은 Exhibit 15.1로 첨부되어 있습니다.

이번 변경은 거버넌스 변화를 의미하지만 감사 일정은 유지됩니다. 투자자들은 2025 회계연도 감사 전에 언급된 통제 약점 개선을 주시해야 합니다.

Concorde International Group Ltd (CIGL) a déposé un formulaire 6-K annonçant un changement d’auditeur effectif au 1er août 2025. Le comité d’audit a révoqué Kreit & Chiu CPA LLP, dont les opinions d’audit pour 2023-24 étaient sans réserve et ne comportaient aucune restriction de portée ni réserve relative aux normes comptables. Le cabinet n’a signalé aucun désaccord avec la direction sur des questions comptables au cours des deux derniers exercices fiscaux.

Le comité a simultanément nommé Assentsure PAC pour auditer l’exercice 2025 et examiner les résultats du premier semestre 2025. La société confirme qu’Assentsure n’a pas été consultée auparavant sur des questions comptables ou de reporting.

Bien qu’aucun événement signalable lié à Kreit & Chiu n’ait été identifié, le dépôt rappelle les faiblesses importantes précédemment divulguées dans le contrôle interne sur la communication financière – principalement des lacunes dans la séparation des fonctions, une formation IFRS insuffisante et des contrôles de révision inefficaces. La lettre de Kreit & Chiu adressée à la SEC, approuvant ces divulgations, est jointe en annexe 15.1.

Ce changement marque une évolution de la gouvernance tout en maintenant le calendrier d’audit ; les investisseurs doivent suivre la correction des faiblesses de contrôle citées avant l’audit de l’exercice 2025.

Concorde International Group Ltd (CIGL) hat ein Formular 6-K eingereicht, in dem ein Wechsel des Abschlussprüfers zum 1. August 2025 angekündigt wird. Der Prüfungsausschuss hat Kreit & Chiu CPA LLP abberufen, dessen Prüfungsurteile für 2023-24 uneingeschränkt waren und keine Einschränkungen im Umfang oder bei den GAAP enthielten. Die Firma meldete in den letzten zwei Geschäftsjahren keine Meinungsverschiedenheiten mit dem Management zu Rechnungslegungsfragen.

Gleichzeitig wurde Assentsure PAC mit der Prüfung des Geschäftsjahres 2025 sowie der Überprüfung der Ergebnisse des ersten Halbjahres 2025 beauftragt. Das Unternehmen bestätigt, dass Assentsure vorher nicht zu Buchhaltungs- oder Berichtsthemen konsultiert wurde.

Obwohl keine meldepflichtigen Ereignisse im Zusammenhang mit Kreit & Chiu vorlagen, wiederholt die Einreichung zuvor offengelegte wesentliche Schwächen in der internen Kontrolle über die Finanzberichterstattung – hauptsächlich Lücken bei der Aufgabentrennung, unzureichende IFRS-Schulungen und ineffektive Überprüfungskontrollen. Das Schreiben von Kreit & Chiu an die SEC, das diesen Angaben zustimmt, ist als Exhibit 15.1 beigefügt.

Der Wechsel signalisiert eine Veränderung in der Governance, hält jedoch den Prüfungszeitplan ein; Investoren sollten die Behebung der genannten Kontrollschwächen vor der Prüfung für das Geschäftsjahr 2025 beobachten.

false 0001053691 0001053691 2025-08-05 2025-08-05
 
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
August 5, 2025
Date of Report (Date of earliest event reported)
 

 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
 

 
Delaware
001-37942
30-0645032
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
   
20 Park Plaza, Suite 424
Boston, Massachusetts
02116
(Address of principal executive offices)
(Zip Code)
 
Registrants telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.001 par value
 
CRVO
 
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 7.01         Regulation FD Disclosure
 
Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the “Company”) has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.
 
The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.
 
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
 
Item 9.01                  Financial Statements and Exhibits
 
(d)         Exhibits
 
Exhibit No.
Description
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 5, 2025
CervoMed Inc.
 
       
 
By:
/s/ William Elder
 
 
Name:
William Elder
 
 
Title:
Chief Financial Officer & General Counsel
 
 
 
CervoMed

NASDAQ:CRVO

CRVO Rankings

CRVO Latest News

CRVO Latest SEC Filings

CRVO Stock Data

76.85M
5.79M
33.38%
26.29%
1.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON